LKFT vs LXEO: fair value comparison
Lakefront Biotherapeutics NV and Lexeo Therapeutics, Inc. · Updated 2026-10-19
LKFT reports in EUR, so no same-currency fair-value verdict is published for it. LXEO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, LKFT currently ranks higher by quality score.
| LKFT | LXEO | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $28.86 | $2.64 |
| 12-month range | $26.08–$34.64 | $2.63–$10.63 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #247 of 301 Healthcare | #248 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | — |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: LKFT fair value analysis · LXEO fair value analysis